Scienture Holdings shares surge 11.81% intraday following FDA-approved REZENOPY® naloxone nasal spray launch and U.S. commercialization plans.
ByAinvest
Tuesday, Dec 23, 2025 11:41 am ET1min read
SCNX--
Scienture Holdings surged 11.81% in intraday trading following the announcement of its high-strength REZENOPY® naloxone HCl nasal spray's commercial launch. The FDA-approved product, developed under an exclusive agreement with Summit Biosciences, is set for wholesale distribution in Q1 2026 and market availability by early Q2 2026. This expansion into opioid overdose treatments underscores the company’s strategic focus on addressing a critical U.S. healthcare need, positioning REZENOPY as a high-potential therapeutic option in a growing market. The news directly aligns with the stock’s upward movement, reflecting investor optimism over the product’s commercial viability and market impact.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet